Restless Legs Syndrome (RLS) Clinical Trial
Official title:
Pilot Study of the Efficacy of Tyrosine in Restless Legs Syndrome
Tyrosine is a non essential amino acid that is the precursor of the neurotransmitter, dopamine. Tyrosine is converted into Levodihydrophenylalanine (L-Dopa) and L-Dopa is subsequently and avidly converted into dopamine. It is well known that dopamine deficiency leads to the manifestations of restless legs syndrome (RLS). Studies have shown dopamine agonists and L-dopa to be effective in controlling symptoms. No studies to date have been done to determine the role of tyrosine in RLS. This open-label pilot study aims to determine the efficacy and tolerability of tyrosine in RLS, as current agents have limitations in treating RLS in addition to adding another possible agent to the investigators arsenal of treating RLS that maybe more cost efficient. In this pilot study, the dose of tyrosine will be escalated from 750 mg once daily by mouth (PO) up to 3000 mg once daily PO, as tolerated, in increments of 750 mg every week in patients who meet the inclusion criteria for RLS. Patients' symptoms will be monitored on a weekly basis for six weeks.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00748098 -
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
|
Phase 3 | |
| Completed |
NCT00373542 -
12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
|
Phase 4 | |
| Completed |
NCT01981941 -
Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
|
Phase 4 | |
| Completed |
NCT01823770 -
Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome
|
Phase 4 | |
| Completed |
NCT00256854 -
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
|
Phase 3 | |
| Completed |
NCT03053427 -
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
|
Phase 4 | |
| Completed |
NCT01382901 -
Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)
|
Phase 2 | |
| Completed |
NCT01411124 -
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects
|
Phase 1 | |
| Terminated |
NCT02826681 -
Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia
|
Phase 2 | |
| Completed |
NCT02397057 -
Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS
|
Phase 3 | |
| Completed |
NCT00314860 -
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
|
Phase 3 | |
| Completed |
NCT00363857 -
A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
|
Phase 3 |